Developer / Researcher,Treatment vs. Vaccine,Product Category,Stage of Development,Anticipated Next Steps,Product Description,Clinical Trials for COVID-19,Funder,Published Results,Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only),FDA-Approved Indications,Sources,Date Last Updated
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma",Vaccine,DNA-based,Phase I,Phase I to start in July 2020,DNA vaccine (GX-19),NCT04445389,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices,Vaccine,DNA-based,Phase I,"Phase I/IIa trial began July 2020; Phase I initial data released June 30, 2020",DNA plasmid vaccine with electroporation; INO-4800,"NCT04336410, NCT04447781",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense,Inovio (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx),Same platform as multiple vaccine candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/17/2020
Zydus Cadila Healthcare Limited ,Vaccine,DNA-based,Phase I,Phase I/II began in July 2020 ,DNA plasmid (ZyCoV-D),CTRI/2020/07/026352,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/16/2020
BioNet Asia,Vaccine,DNA-based,Pre-clinical,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/20/2020
Chula Vaccine Research Center,Vaccine,DNA-based,Pre-clinical,Unknown,DNA with electroporation,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
Ege University,Vaccine,DNA-based,Pre-clinical,Unknown,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Entos Pharmaceuticals/ Cytiva,Vaccine,DNA-based,Pre-clinical,Phase I/II to start in late July 2020 ,DNA; Covigenix,,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/1/2020
Immunomic Therapeutics / EpiVax / PharmaJet,Vaccine,DNA-based,Pre-clinical,Unknown,"DNA plasmid, needle-free delivery",,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Mediphage Bioceuticals/ University of Waterloo,Vaccine,DNA-based,Pre-clinical,Unknown,msDNA vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"National
  Research Centre, Egypt",Vaccine,DNA-based,Pre-clinical,Unknown,"DNA plasmid vaccine S, S1, S2, RBD & N",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
OPENCORONA - Cobra Biologics / Karolinska Institute,Vaccine,DNA-based,Pre-clinical,Phase I to start in 2020,DNA with electroporation,,European Commission (Horizon 2020 Program),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Osaka University/ AnGes/ Takara Bio/ Cytiva,Vaccine,DNA-based,Pre-clinical,Phase I to start in July 2020,"DNA plasmid, vaccine + adjuvant",NCT04463472,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
Scancell/ University of Nottingham/ Nottingham Trent University,Vaccine,DNA-based,Pre-clinical,Phase I to start in Q1 2021,DNA plasmid vaccine RBD&N,,Unknown,,Same platform as vaccine candidates for cancer,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Statens Serum Institute, Denmark",Vaccine,DNA-based,Pre-clinical,Phase I is expected to start in late 2020 or early 2021,"DNA plasmid, CoVAXIX",,"Statens Serum Institute, Denmark",,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Symvivo,Vaccine,DNA-based,Pre-clinical,Unknown,"bacTRL-Spike
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Takis/ Applied DNA Sciences/ Evvivax,Vaccine,DNA-based,Pre-clinical,Animal results released in May 2020; Phase I to start in fall 2020,DNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/17/2020
Wuhan Institute of Biological Products/ Sinopharm,Vaccine,Inactivated virus,Phase III,Phase III trial began July 2020; Early Phase I/II trial results released June 2020,Inactivated," ChiCTR2000031809, ChiCTR2000034780",Unknown,(https://www.cnbg.com.cn/content/details_12_5545.html),,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
Beijing Institute of Biological Products/ Sinopharm,Vaccine,Inactivated virus,Phase II,"In Phase II, June 2020",Inactivated,"ChiCTR2000032459, ChiCTR2000034780",Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Vaccine,Inactivated virus,Phase II,Phase II began June 2020,Inactivated,NCT04412538,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Sinovac/ Instituto Butantan,Vaccine,Inactivated virus,Phase II,Phase III enrolling in Brazil in July 2020; Phase II started in June 2020; preliminary results from Phase I/II trials released June 2020,Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc),"NCT04456595, NCT04352608, NCT04383574",Unknown,(http://www.sinovac.com/?optionid=754&auto_id=904),Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
"Beijing Minhai Biotechnology Co., Ltd.",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Bharat Biotech,Vaccine,Inactivated virus,Pre-clinical,Phase I/II to start in July 2020,Whole-Virion Inactivated (COVAXIN),CTRI/2020/07/026300,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/16/2020
KM Biologics,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated (inactivated + alum),,Unknown,,"Same platform as vaccine candidates for JE, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"National Research Centre, Egypt",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated whole virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
Osaka University / BIKEN / NIBIOHN,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Selcuk University,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Sinovac/ Dynavax,Vaccine,Inactivated virus,Pre-clinical,Unknown,Inactivated (inactivated + CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Valneva/ Dynavax,Vaccine,Inactivated virus,Pre-clinical,Unknown,"Inactivated (Inactivated + CpG 1018), VLA2001",,Unknown,,Same platform as vaccine candidates for Japanese Encephalitis,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Codagenix / Serum Institute of India,Vaccine,Live attenuated virus,Pre-clinical,Animal data in summer 2020,Codon deoptimized live attenuated virus,,Unknown,,"Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Indian Immunologicals Ltd/ Griffith University,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated virus,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Vaccine,Live attenuated virus,Pre-clinical,Unknown,Codon deoptimized live attenuated vaccines,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Meissa Vaccines ,Vaccine,Live attenuated virus,Pre-clinical,Start Phase 1 beginning of 2021,MV-014-210,,Unknown,,Same platform as vaccine candidates for RSV,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/2/2020
"Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca/IQVIA ",Vaccine,Non-replicating viral vector,Phase III,Interim results from ongoing Phase I/II trial released in July 2020; Phase III enrolling in Brazil end of June 2020; South African trial starts end of June 2020; Will join US Operation Warp Speed Phase III vaccine trials in August 2020; Phase II/III trials enrolling May 2020,Non-replicating viral vector; AZD 1222 (formerly ChAdOx1),"ISRCTN89951424, NCT04324606, EudraCT 2020-001072-15, EudraCT 2020-001228-32, NCT04400838, ISRCTN89951424, PACTR202006922165132","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance",The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext),"Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council ,Vaccine,Non-replicating viral vector,Phase II,"Approved for military use in China on June 25, 2020; Phase II started April 2020; initial results released May 2020",Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV),NCT04313127 ChiCTR2000030906 ChiCTR2000031781 NCT04398147,Unknown,The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext),Same platform as vaccine candidates for EBOV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Gamaleya  Research Institute,Vaccine,Non-replicating viral vector,Phase I,Unknown,Adeno-based,NCT04437875,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Altimmune / University of Alabama at Birmingham,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I trial to begin Q3 2020,"AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Ankara University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Bharat Biotech/ Thomas Jefferson University,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Recombinant deactivated rabies virus containing S1,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,"Non-replicating viral vector, MVA expressing structural proteins",,Unknown,,"Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
DZIF - German Center for Infection Research/ IDT Biologika GmbH,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; MVA-S encoded,,Unknown,,Same platform as vaccine candidates for many pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
GeoVax / BravoVax,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; MVA encoded VLP,,Unknown,,"Same platform as vaccine candidates for LASV, EBOV, MARV, HIV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Greffex,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; Ad5 S (GREVAX™ platform),,Unknown,,"Same platform as vaccine candidates for MERS
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",Vaccine,Non-replicating viral vector,Pre-clinical,Phase 1 to begin second half of 2020,"AAVCOVID, Adeno-associated viral vector (AAV), spike protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
ID Pharma,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Sendai virus vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,MVA-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
ImmunityBio/ NantKwest,Vaccine,Non-replicating viral vector,Pre-clinical,Start Phase I in June 2020; vaccine to be included in US Operation Warp Speed trials according to company,"Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid",,Unknown,,"Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent,Vaccine,Non-replicating viral vector,Pre-clinical,"Will join US Operation Warp Speed vaccine trials in September 2020; Phase I/IIa to start in July 2020, initial results expected in September 2020","Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)",,Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Ebola, HIV, RSV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/17/2020
"National
  Research Centre, Egypt",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Influenza A H1N1 vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
ReiThera/ Leukocare/ Univercells,Vaccine,Non-replicating viral vector,Pre-clinical,Start Phase I in summer 2020,Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Stabilitech Biopharma Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Oral Ad5 S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
University of Georgia/ University of Iowa,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein,,Unknown,,Same platform as vaccine candidates for MERS ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
University of Manitoba,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Non-replicating viral vector; dendritic cell-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/20/2020
Valo Therapeutics Ltd,Vaccine,Non-replicating viral vector,Pre-clinical,Unknown,Adenovirus-based + HLA-matched peptides (Pan-Corona),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Vaxart / Emergent BioSolutions,Vaccine,Non-replicating viral vector,Pre-clinical,Phase I trial to begin in the second half of 2020,"Non-replicating viral vector; Oral Vaccine
 platform",,Unknown,,"Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Clover Biopharmaceuticals Inc./ GSK/ Dynavax,Vaccine,Protein subunit,Phase I,"CEPI partnership expanded in July 2020, Phase I trial started June 2020, preliminary results expected August 2020","Protein subunit, native like trimeric subunit spike protein",NCT04405908,Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for HIV, RSV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics,Vaccine,Protein subunit,Phase I,"Will join US Operation Warp Speed vaccine trials, Phase III trial to start in fall 2020; Phase I/II started May 2020; top-line data expected July 2020",Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373),NCT04368988,Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense,,"Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
University of Queensland/CSL/Seqirus,Vaccine,Protein subunit,Phase I,Phase I trial started July 2020,Protein subunit; molecular clamp stabilized Spike protein with MF59 adjuvant,ACTRN12620000674932p,Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation,,"Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma,Vaccine,Protein subunit,Phase I,Phase I trial started July 2020,Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19),NCT04453852,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
AJ Vaccines,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",Vaccine,Protein subunit,Pre-clinical,Phase II to start as early as July 2020; Phase I preliminary results expected in September 2020; Received approval to launch clinical trials in China in June 2020,Adjuvanted recombinant protein (RBD-Dimer),"NCT04445194, NCT04466085",Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/16/2020
AnyGo Technology,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S1-Fc fusion protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"Applied Biotechnology Institute, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Orally delivered, heat stable subunit",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Axon Neuroscience SE,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptides derived from Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Baiya Phytopharm/ Chula Vaccine Research Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Plant-based subunit (RBD-Fc + Adjuvant),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
Baylor College of Medicine,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S1 or RBD protein,,Unknown,,Same platform as vaccine candidates for SARS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Biological E Ltd,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; adjuvanted protein subunit (RBD),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
BiOMVis Srl/ University of Trento,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Bogazici University,Vaccine,Protein subunit,Pre-clinical,Unknown,Peptide + novel adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Chulalongkorn University/ GPO, Thailand",Vaccine,Protein subunit,Pre-clinical,Unknown,RBD protein fused with Fc of IgG + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
EpiVax ,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit EPV-CoV-19,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
EpiVax / University of Georgia,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,Same platform as vaccine candidates for Inf H7N9,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ExpreS2ion,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, drosophila S2 insect cell expression system VLPs",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; peptide vaccine,,Unknown,,Same platform as vaccine candidates for Ebola,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; subunit vaccine,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Flow Pharma,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, peptide",,Unknown,,"Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer ",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Generex / EpiVax,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; Ii-Key peptide,,Unknown,,"Same platform as vaccine candidates for HIV, SARS-CoV, Influenza",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit (gp-96 backbone),,Unknown,,"Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/9/2020
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Vaccine,Protein subunit,Pre-clinical,Unknown,Subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
iBio / CC-Pharming,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit; Subunit protein, plant produced",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
ImmunoPrecise/ LiteVax BV,Vaccine,Protein subunit,Pre-clinical,Unknown,Spike-based (epitope screening),,TRANSVAC2,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Vaccine,Protein subunit,Pre-clinical,"Phase I to start by Summer 2020, results expected by Fall 2020; Phase II expected to start in the second half of 2020","Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",,Unknown,,"Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
InnoMedica,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, TaliCoVax19 ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Innovax / Xiamen University / GSK,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; COVID-19 XWG-03 truncated Spike proteins,,Unknown,,"Same platform as vaccine candidates for HPV  
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
Intravacc/Epivax,Vaccine,Protein subunit,Pre-clinical,Unknown,Outer Membrane Vesicle (OMV)-subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
Izmir Biomedicine and Genome Center,Vaccine,Protein subunit,Pre-clinical,Unknown,Recombinant S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Kentucky BioProcessing (British American Tobacco),Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-based,NCT04473690,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/21/2020
"LakePharma, Inc.",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, nanoparticle vaccine",,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Lomonosov Moscow State University,Vaccine,Protein subunit,Pre-clinical,Unknown,Structurally modified spherical particles of the tobacco mosaic virus (TMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
Max-Planck Institute of Colloids and Interfaces,Vaccine,Protein subunit,Pre-clinical,Unknown,Targeted (Langerhans cell specific) protein subunit; spike based,,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,Vaccine,Protein subunit,Pre-clinical,Unknown,S-2 P protein + CpG 1018,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
MIGAL Galilee Research Institute,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; oral E. coli-based protein expression system of S and N proteins,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"MOGAM Institute for Biomedical Research, GC Pharma",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/5/2020
Mynvax,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"National
  Research Centre, Egypt",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein Subunit S, N, M & S1 protein",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"National Institute of Infectious Disease, Japan",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, S protein + adjuvant",,Unknown,,Same platform as vaccine candidates for Influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Neovii/Tel Aviv University,Vaccine,Protein subunit,Pre-clinical,Unknown,RBD-based,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
OncoGen,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, VLP-recombinant protein + adjuvant",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
PDS Biotechnology,Vaccine,Protein subunit,Pre-clinical,Unknown,PDS-0203; Versamune T-cell activating technology ,,Unknown,,"Same platform as vaccines against cancers, HBV, influenza, and tuberculosis",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
"PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic",Vaccine,Protein subunit,Pre-clinical,Phase I to begin by February 2021,"Protein subunit, capsid-like particle (CLP)",,European Commission (Horizon 2020 Program),,Same platform as vaccine candidates for HPV  ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/14/2020
Quadram Institute Biosciences,Vaccine,Protein subunit,Pre-clinical,Unknown,OMV-based vaccine,,Unknown,,"Same platform as vaccine candidates for Flu A, plaque
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Sanofi Pasteur / GSK,Vaccine,Protein subunit,Pre-clinical,Phase I/II to start in September 2020,"Protein subunit; S protein, baculovirus production",,Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/8/2020
St. Petersburg Scientific Research Institute of Vaccines and Serums,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
UMN Pharma (Shionogi),Vaccine,Protein subunit,Pre-clinical,Phase I to start by end of 2020,"Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",,Japan Agency for Medical Research and Development,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020
University of Alberta,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; spike based,,Unknown,,Same platform as vaccine candidates for Hepatitis C,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"University of California, San Diego",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch,,National Science Foundation (Rapid Response Research [RAPID] grant),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
University of Cambridge / DIOSynVax,Vaccine,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,Protein subunit; S protein,,Unknown,,"Influenza, Ebola",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Pittsburgh,Vaccine,Protein subunit,Pre-clinical,Phase I to start as early as June 2020,"PittCoVacc, Protein subunit, microneedle arrays S1 subunit",,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"University of San Martin and CONICET, Argentina",Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/12/2020
University of Virginia,Vaccine,Protein subunit,Pre-clinical,Unknown,S subunit intranasal liposomal formulation with GLA/3M052 adjs.,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Vabiotech,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant S protein in IC-BEVS  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Vaxil Bio,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; peptide,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
"Verndari/ University of California, Davis",Vaccine,Protein subunit,Pre-clinical,Phase I to start summer 2020,Spike protein; VaxiPatch microneedle array dermal patch,,Unknown,,Same platform as vaccines against influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
"VIDO-InterVac, University of Saskatchewan",Vaccine,Protein subunit,Pre-clinical,Animal testing results expected in April 2020,"Protein subunit, adjuvanted microsphere peptide",,The Government of Saskatchewan and the Canadian Federal Government,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
WRAIR / USAMRIID,Vaccine,Protein subunit,Pre-clinical,Unknown,Protein subunit; S protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Yisheng Biopharma,Vaccine,Protein subunit,Pre-clinical,Unknown,"Protein subunit, recombinant protein  ",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Aurobindo,Vaccine,Replicating viral vector,Pre-clinical,Unknown,VSV-S,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
BIOCAD / IEM,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
DZIF - German Center for Infection Research/ CanVirex AG,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Measles virus (S, N targets)",,Unknown,,"Same platform as vaccine candidates for Zika, H7N9, CHIKV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Fundacao Oswaldo Cruz and Instituto Buntantan,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Attenuated Influenza expressing an antigenic portion of the Spike protein,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/27/2020
IAVI/ Merck,Vaccine,Replicating viral vector,Pre-clinical,Will join US Operation Warp Speed vaccine trials; clinical studies to start in 2020,"Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein",,Biomedical Advanced Research and Development Authority (BARDA),,"Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
Institut Pasteur / Themis / University of Pittsburgh / Merck,Vaccine,Replicating viral vector,Pre-clinical,Start animal testing in April 2020; clinical testing to start later in 2020,Replicating viral vector; measles vector,,Coalition for Epidemic Preparedness (CEPI),,"Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/28/2020
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Newcastle disease virus vector (NDV-SARS-CoV-2/Spike),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Vaccine,Replicating viral vector,Pre-clinical,Unknown,VSV-S ,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
KU Leuven,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; YF17D Vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"The Lancaster University, UK",Vaccine,Replicating viral vector,Pre-clinical,Unknown,Avian paramyxovirus vector (APMV),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
The University of Hong Kong,Vaccine,Replicating viral vector,Pre-clinical,Unknown,"Replicating viral vector, influenza vector expressing RBD",,Coalition for Epidemic Preparedness (CEPI),,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Tonix Pharma / Southern Research,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; horsepox vector expressing S protein; TNX-1800,,Unknown,,"Same platform as vaccine candidates for smallpox, monkeypox",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
University of Western Ontario,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; VSV-S,,Unknown,,"Same platform as vaccine candidates for HIV, MERS",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Wisconsin-Madison / FluGen/ Bharat Biotech,Vaccine,Replicating viral vector,Pre-clinical,Start Phase I trial in fall 2020,M2-deficient single replication (M2SR) influenza vector,,Unknown,,Same platform as vaccine candidates for influenza,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Zydus Cadila Healthcare Limited ,Vaccine,Replicating viral vector,Pre-clinical,Unknown,Replicating viral vector; measles vector,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Moderna/ NIAID/ Lonza/ Catalent/ Rovi/ Medidata,Vaccine,RNA-based vaccine,Phase II,Interim analysis results of Phase I study published in July 2020; will join US Operation Warp Speed vaccine Phase III trials in July 2020; Completed enrollment for both cohorts of the Phase II study in early July 2020; FDA granted fast track designation May 2020,RNA; LNP-encapsulated mRNA (mRNA 1273),"NCT04283461, NCT04405076, NCT04470427",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA),"Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine), NEJM (https://www.nejm.org/doi/full/10.1056/NEJMoa2022483)",Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
BioNTech/ Fosun Pharma/ Pfizer,Vaccine,RNA-based vaccine,Phase I,Joined US Operation Warp Speed in July 2020; FDA granted Fast Track designation for two BNT162 candidates (BNT162b1 and BNT162b2); Phase IIb/III trial may start as early as July 2020; Phase I/II started April 2020; preliminary data from ongoing Phase I/II trial released July 2020,"3 LNP-mRNAs; BNT162 
","EudraCT 2020-001038-36, NCT04368728, ChiCTR2000034825",Unknown,"Pfizer (https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing-0), medRxiv (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1), medRxiv (https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1)",,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
CureVac,Vaccine,RNA-based vaccine,Phase I,Start Phase I/IIa trial June 2020,RNA; mRNA,NCT04449276,Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB),,"Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
Imperial College London/ VacEquity Global Health,Vaccine,RNA-based vaccine,Phase I,Phase I/II trial started June 2020,RNA; LNP-nCoVsaRNA,ISRCTN17072692,UK Government,,"Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"Arcturus/Duke-NUS/ Catalent
",Vaccine,RNA-based vaccine,Pre-clinical,Start Phase I trial August 2020,LUNAR-COV19; RNA; mRNA,NCT04480957,Unknown,,Same platform as vaccine candidates for multiple candidates,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/24/2020
BIOCAD,Vaccine,RNA-based vaccine,Pre-clinical,Animal studies begin in April 2020,RNA; liposome-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for cancer   ,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
CanSino Biologics/Precision Nanosystems,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA lipid nanoparticle (mRNA-LNP),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/21/2020
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; Replicating defective SARS-CoV-2 derived RNAs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"Self amplifying RNA, self-assembling delivery system",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
China CDC / Tongji University / Stermina,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Chula Vaccine Research Center/University of Pennsylvania,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,LNP-mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/26/2020
Elixirgen Therapeutics,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,srRNA (EXG-5003),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/23/2020
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,Vaccine,RNA-based vaccine,Pre-clinical,Start Phase I early 2021,RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA cocktail encoding RBD,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
GeneOne Life Science / Houston Methodist,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Gennova,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"Self-amplifying
  RNA",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/15/2020
"Greenlight Biosciences
",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
"IDIBAPS- Hospital Clinic, Spain",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
Max Planck Institute of Colloids and Interfaces,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA in targeted LPNs (Langerhans cell specific),,KHAN-1 Technology Transfer Fund I GmbH & Co KG,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,ChiCTR2000034112,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
"RNAimmune, Inc.",Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; several mRNA candidates,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Sanofi Pasteur / Translate Bio,Vaccine,RNA-based vaccine,Pre-clinical,Phase I to start Q4 2020,"LNP-mRNA
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/24/2020
Selcuk University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,mRNA,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
University of Tokyo / Daiichi-Sankyo,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,RNA; LNP-encapsulated mRNA,,Unknown,,Same platform as vaccine candidates for MERS,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Ziphius Therapeutics/ Ghent University,Vaccine,RNA-based vaccine,Pre-clinical,Unknown,"RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/28/2020
Medicago Inc.,Vaccine,Virus-like particle,Phase I,Phase I started July 2020; Phase II/III is expected to start by October 2020,VLP; plant-derived VLP adjuvanted with GSK or Dynavax adjs.,NCT04450004,Unknown,,"Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/17/2020
"ARTES Biotechnology
",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; eVLP,,Unknown,,"Same platform as vaccine candidates for malaria
",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/4/2020
Bezmialem Vakif University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/21/2020
Doherty Institute,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/8/2020
Imophoron Ltd / Bristol University's Max Planck Centre,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP; ADDomerTM multiepitope display,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Vaccine,Virus-like particle,Pre-clinical,Unknown,S protein integrated in HIV VLPs,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/23/2020
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP + Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"Medicago
  Inc./ GSK",Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (CoVLP)+ Adjuvant,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/14/2020
Medicago Inc./ Dynavax,Vaccine,Virus-like particle,Pre-clinical,Phase I to start mid-July 2020,VLP (CoVLP)+ Adjuvant (CpG 1018),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/10/2020
Middle East Technical University,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
"Navarrabiomed, Oncoimmunology group",Vaccine,Virus-like particle,Pre-clinical,Unknown,"Virus-like particles, lentivirus, and baculovirus vehicles",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/1/2020
OSIVAX,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLP (COVID-19 and SARS1),,European Innovation Council (EIC),,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/9/2020
Saiba GmbH,Vaccine,Virus-like particle,Pre-clinical,Unknown,"VLP; virus-like particle, based on RBD displayed on virus-like particle",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
University of Sao Paulo,Vaccine,Virus-like particle,Pre-clinical,Unknown,VLPs peptides/whole virus,,Unknown,,,,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/19/2020
VBI Vaccines / National Research Council of Canada,Vaccine,Virus-like particle,Pre-clinical,Start Phase I testing by end of 2020,"Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein",,Unknown,,"Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika",N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
AbVision,Vaccine,Unknown,Pre-clinical,Unknown,AVI-205,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/13/2020
Adeleke University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/30/2020
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/23/2020
Codiak BioSciences/ Ragon Institute,Vaccine,Unknown,Pre-clinical,Unknown,exoVACC exome platform,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/4/2020
Covaxx,Vaccine,Unknown,Pre-clinical,Phase I to start in summer 2020,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID),Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/24/2020
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,Vaccine,Unknown,Pre-clinical,Animal study results by October 2020,"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",,Analog Devices Foundation,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,4/21/2020
ISR Immune System Regulation,Vaccine,Unknown,Pre-clinical,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",ISR-50,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
NidoVax,Vaccine,Unknown,Pre-clinical,Unknown,unknown; IMT504 technology,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/18/2020
"Oragenics (Noachis Terra)/ Aragen Bioscience
",Vaccine,Unknown,Pre-clinical,Phase I expected to start in early 2021,"TerraCoV2
",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,7/23/2020
Precision Vaccines Program at Boston Children's Hospital,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Shenzhen Geno-Immune Medical Institute,Vaccine,Unknown,Pre-clinical,Unknown,Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins,NCT04299724,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
Shenzhen Geno-Immune Medical Institute,Vaccine,Unknown,Pre-clinical,Unknown,LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes,NCT04276896,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/12/2020
SK Biosciences,Vaccine,Unknown,Pre-clinical,Phase I begins as early as September 2020,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
SmartPharm Therapeutics / Sorrento Therapeutics,Vaccine,Unknown,Pre-clinical,Unknown,"Gene-encoded antibody vaccine, non-viral nanoparticle delivery",,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Tulane University,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vault Pharma/ University of California Los Angeles,Vaccine,Unknown,Pre-clinical,Unknown,nanoparticles (vaults) as second-line defense of infection,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/17/2020
Vir Biotechnology / GSK,Vaccine,Unknown,Pre-clinical,Unknown,Unknown,,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,Prior to 4/20/2020
Vivaldi Biosciences/ Esco Aster Pte Ltd,Vaccine,Unknown,Pre-clinical,Unknown,Chimeric vaccine (coronavirus and influenza),,Unknown,,,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,6/2/2020
"University of California, Los Angeles (Horwitz Lab)",Vaccine,Replicating bacterial vector,Pre-clinical,Unknown,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens,,Unknown,,Same platform as vaccines against select agents and emerging pathogens,N/A,https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit,5/10/2020